Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
obesity drugs
Biotech
Lilly withdraws phase 2 obesity trial before starting enrollment
The study was designed to test bimagrumab, an asset Lilly acquired in its $1.9 billion Versanis buyout, and blockbuster GLP-1/GIP drug tirzepatide.
Nick Paul Taylor
Sep 25, 2025 8:07am
Pfizer inks $4.9B Metsera buyout to beef up obesity pipeline
Sep 22, 2025 7:47am
QL Biopharm links monthly GLP-1 to incumbent-rivaling efficacy
Sep 18, 2025 7:20am
Novo seeks obesity refresh with $550M Replicate deal
Aug 28, 2025 7:00am
Viking hits stormy seas as phase 2 oral obesity data sink stock
Aug 19, 2025 9:44am
Response's ex-Sanofi asset hits goal in post-GLP-1 patients
Aug 13, 2025 9:14am
